Mediar raises $105 million to target fibrotic mediators

Fibrosis-focused Mediar Therapeutics has added $105 million to its coffers.

The US firm’s fundraising includes an $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Ono Venture Investment and Mass General Brigham Ventures.

The latter company co-founded Mediar alongside Mass General and Brigham and Women’s Hospitals with the goal to transform the treatment of fibrotic disease by targeting the myofibroblast, the key cell type driving fibrosis progression.